AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 71 min read$NOVT

Glastra Matthijs sold $1.0M of NOVT

Glastra Matthijs (Chief Executive Officer) sold 6,500 shares of NOVANTA INC (NOVT) at an average of $161.13 ($160.13–$164.20, $1.05M total) across 5 trades on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Glastra Matthijs
Published Jul 7, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NOVT
Neutral
high confidence
Mentioned
$NOVT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NOVTNeutralLow
01

Why it matters

The disclosure updates insider activity but does not introduce new company fundamentals (no guidance, earnings, contracts, or regulatory actions).

02

Market read

Traders may note the sale for sentiment/positioning, but the 10b5-1 framing suggests limited incremental information.

03

What to watch

The article lacks context on total insider holdings history, whether sales were part of a broader planned schedule, and whether any concurrent buys occurred.

Relevance 5/10Novelty 3/10Timing: Filed after-hours on 2026-07-07; reflects trades executed 2026-07-02.

Background

This is an SEC Form 4 insider transaction: CEO Glastra Matthijs executed open-market sales under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NOVTNeutralHigh confidence
Context

Novanta CEO Glastra Matthijs sold 6,500 shares in open-market trades totaling about $1.05M at $160.13–$164.20.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any reaction is likely muted.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement, and it provides no new operating, guidance, or regulatory information.

Market effects

Sector

No clear sector read-through; this is company-specific insider liquidity activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with a 10b5-1 plan, repeated insider selling can coincide with private concerns; traders may still watch for follow-on disclosures.

Key entities

  • issuer
    NOVANTA INC

    Company whose CEO filed the Form 4 insider sale.

  • insider
    Glastra Matthijs

    Chief Executive Officer and director who sold shares totaling ~$1.05M.

Read at source← All news

Related articles

AUG 5
$NOVTHighAI 9/10

Novanta Announces Financial Results for the Second Quarter 2026

Novanta Inc. (Nasdaq: NOVT) reported Q2 2026 GAAP revenue of $265.8 million, up 10.3% year over year, and GAAP net income of $12.5 million. Adjusted EBITDA rose 16.4% to $60.7 million and adjusted diluted EPS increased 17.1% to $0.89. The company also closed the Riverpoint Medical acquisition and raised Q3 and FY 2026 guidance.

leaderpost.com6 min
AUG 5
$NOVTHigh

NOVANTA INC (NOVT): Results of Operations and Financial Condition

NOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 novt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE August 5, 2026 Novanta Announces Financial Results for the Second Quarter 2026 • Second Quarter 2026 GAAP Revenue increased 10% to $266 million • Second Quarter 2026 GAAP Net Income was $13 million, and

SEC EDGAR 8-K6 min
JUL 27
$NOVTMedAI 8/10

Novanta Completes Acquisition of Riverpoint Medical

Novanta Inc. (Nasdaq: NOVT) said it has completed its acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta expects the deal to double recurring medical consumables revenue to about $300 million, raise medical end-market exposure to 60%, deliver high single-digit ROIC by year three, and add $0.18 to $0.25 of adjusted EPS in 2027.

leaderpost.com5 min
JUN 10
$MRVLMed

Stocks Erase Early Gains as Chipmakers Turn Lower

US stocks pared early gains as chipmakers and software firms fell. Marvell, Qualcomm, ARM and others dropped, while ServiceNow and Salesforce also declined. Treasury yields were pressured by a $58B 3-year auction and stronger May existing home sales. In Europe, Bund and gilt yields fell; swaps price a 100% chance of a 25 bp ECB hike. UNFI slid after Q3 sales missed; Nuvalent surged on a $10.6B GSK buyout.

finance.yahoo.com7 min